… achieved significant results in a lung cancer study comparing it to Tevimbra … ). Results from the phase 3 clinical trial, HARMONi-6, for ivonescimab were … metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 …

… biomarkers in lung cancer. Biomarkers in Lung Cancer Lung cancer is the … . There are various clinical trials investigating TP53 restoration, … to 16% of lung cancers, representing a promising … initial datasets, review clinical trial results, assess toxicity …

… for the Study of Lung Cancer (IASLC) SCLC committee … stage (ES) small cell lung cancer (SCLC) and baseline ( … of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … relapsed small cell lung cancer (IDeate-Lung02). Clinical Trials.gov. Updated …

… approximately 80-85% of lung cancers,2 with BRAF V600E … or completion dates for our clinical trials, regulatory submission dates, … data; the risk that clinical trial data are subject to … metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline …

… CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented … of large, randomized clinical trials shows that patients with … melanoma, non-small-cell lung cancer (NSCLC), urothelial carcinoma, … in patients with advanced lung cancer: A retrospective study. …

… non-small cell lung cancer (NSCLC) compared … ve seen in any clinical trial to date. It … non-small cell lung cancer, including combination therapies … more than 1,200 clinical trials.   ### Media Contact …

… HER2-mutant non-small cell lung cancer (NSCLC), according to data from … I/II SOHO-01 clinical trial found that over 70% of … .  “For patients with HER2-mutant lung cancer, treatment options have historically been …

… Excellence in Lung Cancer Care by GO2 for Lung Cancer, a leading … the charge in early lung cancer detection through advanced robotic … treatment and cutting-edge clinical trials—bringing world-class … plans. We also conduct clinical trials, bringing cutting-edge …

… -mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone … 've seen in any clinical trial to date. It shows that … EGFR-mutant non-small cell lung cancer, including combination therapies and monotherapies …

AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with …